By

admin
Over the past couple of years, the U.S. Food and Drug Administration (FDA) has taken a hard-line stance against drug products that were approved under the accelerated approval pathway, but have not met their post-marketing or confirmatory trial commitments.
Read More
Dr. Suzan McNamara knew she was too young to die. At 31, she was diagnosed with a rare disease called Chronic Myeloid Leukemia (CML), and was given only three to five years to live.
Read More
In May 2016, Lee-Anne Pickard, a nurse with close to 20 years of experience in cancer research, was sent an article from the Montreal Gazette. It outlined how Exactis had set up a pan-Canadian network to collect samples from patients for molecular testing in the hopes of matching them to clinical trials. It was her...
Read More
Abstract submission deadline: Tuesday, 26 July 2022 Trial in Progress (“TiP”) abstracts Exactis-01: Clinical Utility of Returning Liquid Biopsy NGS Results in NSCL Cancer Patients – A Canadian Trial through the Exactis Network (NCT04564079) Karen Gambaro 1 , Maud Marques 1 , Andrea Hébert-Losier 1 , Suzan McNamara 1 , Gerald Batist 2 , The...
Read More
Plenary themes under which authors will submit their abstracts: • Registries, research and health policy PERSONALIZE MY TREATMENT (PMT): A CANADIAN CANCER PATIENT REGISTRY. Maud Marques 1 , Karen Gambaro 1 , Vincent Normandeau-Babin 1 , David Bouffard 1 , Ethan Hoang 1 , Suzan McNamara 1 , the Exactis Network, Gerald Batist 1,2 ,...
Read More
IARC
Plenary themes under which authors will submit their abstracts: • Registries, research and health policy PERSONALIZE MY TREATMENT (PMT): A CANADIAN CANCER PATIENT REGISTRY. Maud Marques 1 , Karen Gambaro 1 , Vincent Normandeau-Babin 1 , David Bouffard 1 , Ethan Hoang 1 , Suzan McNamara 1 , the Exactis Network, Gerald Batist 1,2 ,...
Read More
esmo
Abstract submission deadline: Tuesday, 26 July 2022 Trial in Progress (“TiP”) abstracts Exactis-01: Clinical Utility of Returning Liquid Biopsy NGS Results in NSCL Cancer Patients – A Canadian Trial through the Exactis Network (NCT04564079) Karen Gambaro 1 , Maud Marques 1 , Andrea Hébert-Losier 1 , Suzan McNamara 1 , Gerald Batist 2 , The...
Read More
Nous aimerions vous informer de l’évolution naturelle d'Exactis Innovation et de son leadership. De ce fait, nous sommes heureux d'annoncer la nomination de Dr Kostas Trakas à titre de PDG d'Exactis Innovation à compter du 1er février 2022.
Read More
Nous sommes heureux d’avoir été choisi parmi les 39 meilleures entreprises d’essais cliniques au Canada selon le site: https://beststartup.ca/Voici un résumé de l’article: This article showcases our top picks for the best Canada based Clinical Trials companies. These startups and companies are taking a variety of approaches to innovating the Clinical Trials industry, but are...
Read More
1 2 3 4 5